Asian population, normotensive, SBP mmHg · Asian population with normal or elevated blood pressure, but otherwise healthy
1 finding from 1 review
Weight (kg) · Adults or children with overweight or obesity
1 finding from 1 review
Body‐mass index (BMI) · Adults or children with overweight or obesity
1 finding from 1 review
Adverse events (n/N) · Adults or children with overweight or obesity
1 finding from 1 review
Health‐related quality of life Scale · Adults or children with overweight or obesity
1 finding from 1 review
All‐cause mortality · Adults or children with overweight or obesity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · Adults or children with overweight or obesity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Weight (kg) · Adults or children with overweight or obesity
1 finding from 1 review
Body‐mass index (BMI) · Adults or children with overweight or obesity
1 finding from 1 review
Adverse events (n/N) · Adults or children with overweight or obesity
1 finding from 1 review
Health‐related quality of life · Adults or children with overweight or obesity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Treatment failure · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes treatment failure compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Chronic lung disease · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Duration of any form of respiratory support (any form of non‐invasive respiratory support with or without supplemental oxygen) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
ICU length of stay (general intensive care patients) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Adverse events ‐ nasal trauma · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ nasal trauma compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Adverse events ‐ abdominal overdistention · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ abdominal overdistention compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Outcomes · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HRQoL: CRQ total score · patients with chronic obstructive pulmonary disease
1 finding from 1 review